Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Semaglutide’s health benefits beyond diabetes and obesity across multiple body systems

Updated

Abstract

Semaglutide resulted in a 12.4 kg weight reduction and a 1.52% decrease in glycated hemoglobin across 35 trials involving 36,847 participants.

  • Semaglutide is associated with a 16% reduction in major adverse cardiovascular events.
  • A resolution of metabolic dysfunction-associated steatohepatitis was observed in 62.9% of cases.
  • Renal protection was indicated by a hazard ratio of 0.76.
  • Participants showed an improvement in walking distance by 87 meters.
  • There was a favorable change in body composition with an 87:13 fat-to-lean ratio.
  • Quality of life improved by 3.8 points on the SF-36 scale.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Disclosure The authors declare no conflicts of interest related to this work. Neither author has received consulting fees, honoraria, stock ownership, or any other financial relationship with pharmaceutical companies or entities related to semaglutide or GLP-1 receptor agonists.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free